Shanghai Chenguang Medical Technology Co., Ltd. (securities abbreviation: Chenguang Medical, securities code: 430300) was established in 2004 with a registered capital of 6859712600 yuan. It is an independent innovative high-tech enterprise and a small giant enterprise in Shanghai that has long been committed to the R&D, production, sales and maintenance of the core components of the high field strength and ultra-high field strength magnetic resonance industry chain. There are about 269 employees, including 6 doctors and 11 masters. The company has more than 34000 square meters of research and development and production base for high-sensitivity magnetic resonance core components in Qingpu Park, Zhangjiang High-tech Industrial Development Zone, Shanghai. Its three subsidiaries are Chenshi Medical, Chenzhan Medical and Chenhao Superconductor. The products cover core components such as RF system, gradient system and superconducting magnet of magnetic resonance (1.5T, 3.0T, 7.0T), as well as superconducting, normal-conductive magnet, low-temperature equipment, vacuum semiconductor equipment, etc.
The project leaders of Chenguang Medical have rich experience in the development, design and production of superconducting magnetic resonance core components at home and abroad. The magnetic resonance core components designed and produced by them have been applied to the magnetic resonance systems produced by mainstream MRI enterprises at home and abroad. The magnetic resonance radio frequency detector independently developed and produced by Chenguang Medical filled the domestic gap when it entered the registration of medical devices in China. The company also customized and developed a variety of experimental special radio frequency coils for cutting-edge scientific research. Relying on the leading comprehensive engineering capability and after years of research and development accumulation, Chenguang Medical has successfully overcome the technical difficulties of multiple core components in 1.5T, 3.0T and 7.0T magnetic resonance systems. The existing 65 patented technologies have been applied to the R&D and production of magnetic resonance core components. The products have broken the monopoly position of similar international products in China and successfully achieved import substitution. The MR platform solutions provided by the company for Chinese magnetic resonance system manufacturers can be compared with well-known magnetic resonance systems.
Chenguang Medical is committed to legal and compliant operation, has built advanced quality system specifications, and has obtained access qualifications for domestic and international markets. The company has successively passed ISO13485, ISO14001 and European CE certification. Our self-developed core products have passed SFDA certification and UL safety certification of the China Food and Drug Administration. At the same time, products exported to Europe, the United States, Japan and other countries also have FDA certification of the United States Food and Drug Administration and Japan PAL and other international certifications.
Chenguang Medical will continue to improve the company's advanced position in the fields of superconducting magnetic resonance radio frequency detectors, superconducting magnets, etc., gradually expand the industrial chain and application fields of superconducting magnetic resonance, transform from component manufacturers to diversified production and service enterprises, and strive to build "Chenguang Medical" into a Chinese magnetic resonance brand comparable with international enterprises.